SG11201408629QA - Dimethyl-benzoic acid compounds - Google Patents
Dimethyl-benzoic acid compoundsInfo
- Publication number
- SG11201408629QA SG11201408629QA SG11201408629QA SG11201408629QA SG11201408629QA SG 11201408629Q A SG11201408629Q A SG 11201408629QA SG 11201408629Q A SG11201408629Q A SG 11201408629QA SG 11201408629Q A SG11201408629Q A SG 11201408629QA SG 11201408629Q A SG11201408629Q A SG 11201408629QA
- Authority
- SG
- Singapore
- Prior art keywords
- indiana
- company
- international
- iii
- indianapolis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 January 2014 (03.01.2014) WIPOIPCT (10) International Publication Number WO 2014/004230 A1 (51) International Patent Classification: C07D 401/04 (2006.01) C07D 207/08 (2006.01) C07D 211/42 (2006.01) C07D 211/46 (2006.01) A61K31/445 ( 2006.01) A61K31/4709 (2006.01) A61K31/402 (2006.01) A61K31/4025 (2006.01) A61P 29/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/046685 20 June 2013 (20.06.2013) English (30) Priority Data: 61/665,956 61/778,969 29 June 2012 (29.06.2012) 13 March 2013 (13.03.2013) English US US (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). (72) Inventors: BLANCO-PILLADO, Maria-Jesus; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). VETMAN, Tatiana Natali; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indiana polis, Indiana 46206-6288 (US). FISHER, Matthew Joseph; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). KUKLISH, Steven Lee; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (74) Agents: LENTZ, Nelsen L. et al.; ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206- 6288 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, [Continued on next page] (54) Title: DIMETHYL-BENZOIC ACID COMPOUNDS Formula II (57) Abstract: The present invention provides compound a of the Formula II: wherein A is: * R 1 is CH3, CF 3 , or F; * R 2 is H, CH3, or F; * R 3 is CH3, OCH 3 , OH, F; R 4 is OH or CH 20H; and X * is CH or N; These compounds are se lective EP4 inhibitors and are useful for the treatment of in flammatory conditions such as arthritis. wo 2014/004230 AI III llll IIII III III Hill III III III Hill Hill lllll lllll 111 111 lllllll llll 111 llll TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665956P | 2012-06-29 | 2012-06-29 | |
| US201361778969P | 2013-03-13 | 2013-03-13 | |
| PCT/US2013/046685 WO2014004230A1 (en) | 2012-06-29 | 2013-06-20 | Dimethyl-benzoic acid compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408629QA true SG11201408629QA (en) | 2015-01-29 |
Family
ID=48746667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408629QA SG11201408629QA (en) | 2012-06-29 | 2013-06-20 | Dimethyl-benzoic acid compounds |
Country Status (41)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110015221A1 (en) * | 2003-12-23 | 2011-01-20 | Pierre Fabre Medicament | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same |
| TWI572597B (en) * | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | Dimethyl-benzoic acid compounds |
| EP2765128A1 (en) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TWI636046B (en) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | Phenoxyethyl dihydro-1h-isoquinoline compounds |
| CN105793236B (en) | 2013-12-17 | 2017-10-10 | 伊莱利利公司 | Mesitylenic acid compound |
| US10189788B2 (en) * | 2014-09-09 | 2019-01-29 | Bayer Pharma Aktiengesellschaft | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
| CR20180323A (en) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | DERIVATIVES OF INDOL N-SUBSTITUTES AS MODULATORS OF PGE2 RECEIVERS |
| TWI770157B (en) * | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof |
| JP7107963B2 (en) * | 2017-04-10 | 2022-07-27 | バイエル・アクチエンゲゼルシヤフト | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and uses thereof |
| ES2929309T3 (en) | 2017-05-18 | 2022-11-28 | Idorsia Pharmaceuticals Ltd | Benzofuran and benzothiophene derivatives as PGE2 receptor modulators |
| EP3625228B1 (en) | 2017-05-18 | 2021-07-07 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as pge2 receptor modulators |
| HUE056406T2 (en) | 2017-05-18 | 2022-02-28 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| HRP20211533T1 (en) | 2017-05-18 | 2022-01-07 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
| WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| JPWO2022102731A1 (en) | 2020-11-13 | 2022-05-19 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1270615B (en) | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | USE OF QUINOLINE DERIVATIVES |
| JP2000355551A (en) * | 1999-06-15 | 2000-12-26 | Nikken Chem Co Ltd | Pharmaceutical composition |
| ATE412646T1 (en) | 2003-09-22 | 2008-11-15 | Euro Celtique Sa | THERAPEUTIC AGENTS SUITABLE FOR THE TREATMENT OF PAIN |
| US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
| JP5183628B2 (en) * | 2006-06-12 | 2013-04-17 | メルク カナダ インコーポレイテッド | Indoline amide derivatives as EP4 receptor ligands |
| JPWO2008123207A1 (en) * | 2007-03-26 | 2010-07-15 | アステラス製薬株式会社 | Ornithine derivatives |
| WO2012004293A2 (en) | 2010-07-08 | 2012-01-12 | Bayer Cropscience Ag | Insecticide and fungicide active ingredient combinations |
| US20140057953A1 (en) | 2011-03-03 | 2014-02-27 | Rolf Hartmann | Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors |
| TWI572597B (en) * | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | Dimethyl-benzoic acid compounds |
-
2013
- 2013-06-11 TW TW102120796A patent/TWI572597B/en not_active IP Right Cessation
- 2013-06-13 JO JOP/2013/0178A patent/JO3221B1/en active
- 2013-06-13 AR ARP130102078 patent/AR091431A1/en unknown
- 2013-06-20 JP JP2015520305A patent/JP6114824B2/en active Active
- 2013-06-20 ME MEP-2017-83A patent/ME02655B/en unknown
- 2013-06-20 AP AP2014008165A patent/AP4063A/en active
- 2013-06-20 EP EP13734249.9A patent/EP2867218B1/en active Active
- 2013-06-20 MX MX2014015952A patent/MX347476B/en active IP Right Grant
- 2013-06-20 CA CA2875572A patent/CA2875572C/en not_active Expired - Fee Related
- 2013-06-20 SG SG11201408629QA patent/SG11201408629QA/en unknown
- 2013-06-20 EA EA201492140A patent/EA025531B1/en not_active IP Right Cessation
- 2013-06-20 PL PL13734249T patent/PL2867218T3/en unknown
- 2013-06-20 AU AU2013280779A patent/AU2013280779B2/en not_active Ceased
- 2013-06-20 BR BR112014029551A patent/BR112014029551A2/en not_active IP Right Cessation
- 2013-06-20 US US13/922,277 patent/US8642768B2/en not_active Expired - Fee Related
- 2013-06-20 KR KR1020147036136A patent/KR101634032B1/en active IP Right Grant
- 2013-06-20 ES ES13734249.9T patent/ES2623099T3/en active Active
- 2013-06-20 DK DK13734249.9T patent/DK2867218T3/en active
- 2013-06-20 SI SI201330576A patent/SI2867218T1/en unknown
- 2013-06-20 RS RS20170231A patent/RS55756B1/en unknown
- 2013-06-20 CN CN201380030138.XA patent/CN104334540B/en not_active Expired - Fee Related
- 2013-06-20 HU HUE13734249A patent/HUE032398T2/en unknown
- 2013-06-20 MY MYPI2014703973A patent/MY172860A/en unknown
- 2013-06-20 PE PE2014002531A patent/PE20150185A1/en active IP Right Grant
- 2013-06-20 PT PT137342499T patent/PT2867218T/en unknown
- 2013-06-20 IN IN2356MUN2014 patent/IN2014MN02356A/en unknown
- 2013-06-20 NZ NZ701894A patent/NZ701894A/en not_active IP Right Cessation
- 2013-06-20 LT LTEP13734249.9T patent/LT2867218T/en unknown
- 2013-06-20 WO PCT/US2013/046685 patent/WO2014004230A1/en active Application Filing
- 2013-12-04 US US14/096,469 patent/US8933098B2/en not_active Expired - Fee Related
-
2014
- 2014-11-24 ZA ZA2014/08631A patent/ZA201408631B/en unknown
- 2014-11-28 TN TN2014000500A patent/TN2014000500A1/en unknown
- 2014-12-03 CR CR20140554A patent/CR20140554A/en unknown
- 2014-12-11 IL IL236218A patent/IL236218A/en active IP Right Grant
- 2014-12-17 GT GT201400289A patent/GT201400289A/en unknown
- 2014-12-17 DO DO2014000286A patent/DOP2014000286A/en unknown
- 2014-12-18 CO CO14278424A patent/CO7160064A2/en unknown
- 2014-12-26 CL CL2014003537A patent/CL2014003537A1/en unknown
-
2015
- 2015-01-05 PH PH12015500008A patent/PH12015500008B1/en unknown
- 2015-05-07 HK HK15104360.7A patent/HK1203936A1/en not_active IP Right Cessation
-
2017
- 2017-04-03 HR HRP20170540TT patent/HRP20170540T1/en unknown
- 2017-04-12 CY CY20171100435T patent/CY1118830T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408629QA (en) | Dimethyl-benzoic acid compounds | |
| SG11201408800VA (en) | Manufacture of 2- (5- bromo-4-(4-cyclopropylnaphthalen-1-yl) -4h-1,2,4-triazol-3-ylthio) acetic acid | |
| SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
| SG11201808678QA (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201408261UA (en) | Syringe | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201408739VA (en) | Inhibitors of hepatitis c virus | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201406973PA (en) | Complement pathway modulators and uses thereof | |
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201407189XA (en) | C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity | |
| SG11201407184PA (en) | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals | |
| SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201407812SA (en) | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors |